A novel, central parietal electrode positioning for electroconvulsive therapy

Not Applicable

• Conditions: F32; F33; Depressive episode; Recurrent depressive disorder

• Registration Number: DRKS00027373
• Lead Sponsor: VR-Klinikum Düsseldorf, Kliniken der Heinrich-Heine-Universität

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-12-02
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

Ages between 40 and 80 years old
- Suffering from a severe major depression (Symptom criteria based on ICD-10)
- Resistence to at least two antidepressive medications, operationalized though the ATHF (antidepressant treatment history form)
- MADRS-score of 30 or above
- ability to give informed consent

Exclusion Criteria

- contraindication for the necessary anaestheasia
- psychoorganic disorders such as epilepsy, Morbus Parkinson, dementia, stroke or traumatic brain injury
- addiction disorders
- prior treatment with ECT in the index episode
- patients unable to provide informed consent (patients under guardianship)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
- Seizure Quality Parameters <br>- Reduction of depressive Symptoms (operationalized through MADRS)<br>- Changes in cognitive performance (operationalized though the Mini Mental State Test)

Secondary Outcome Measures

Name	Time	Method
Medication needed after ECT, psychopathological symptoms and general protocoll of noteworthy events